Yefang Huang

Yefang Huang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2022 in International Immunopharmacology
Verified
Journal Article
Open access
FLFangyuan Li
Fangyuan Li
HLHua Lu
Hua Lu
YHYefang Huang
Yefang Huang
XWXinxin Wang
Xinxin Wang
QZQi Zhang
Qi Zhang
QYQian Yang
Qian Yang
Currently, whether Hashimoto's thyroiditis decreases ovarian reserve is not clearly known, given the conflicting findings from previous studies. This study was conducted to systematically review and summarize the association of Hashimoto's thyroiditis (HT) with ovarian reserve. Studies investigating ovarian reserve in women with HT and the incidence of HT in women with premature ovarian aging (POA) were searched in major electronic databases. Pre-specified subgroup analyses were performed in terms of agedistribution and thyroidfunction. A total of 935 studies were retrieved from which 30 were included in the meta-analysis and 5 were finallyselectedfor detailed review. Overall, no statistically significant difference in ovarian reserve parameters (AMH, AFC, FSH, E2) between females with HT and the controls. In subgroup meta-analyses, reproductive aged women with HT had a statistically significant reduction in AMH (SMD -0.35; 95% CI: -0.51, -0.19; P<0.0001; I2 = 52%), AFC (MD -0.43; 95% CI: -0.56, -0.30; P<0.00001; I2 = 62%), and increase in basal FSH (SMD 0.1; 95% CI: 0.01, 0.19; I2 = 19%; P = 0.04) compared with age matched controls. Furthermore, POA inreproductive aged women wasassociatedwith higher frequency ofpositiveTPOAb (OR 2.26, 95% CI: 1.31-3.92, p = 0.004) but not positive TgAb(OR 3.17, 95% CI: 0.89-11.38, p = 0.08). These bidirectional associations suggested that reproductive aged women with HT have a significantly higher risk of diminished ovarian reserve.

20 September 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
YZYuanyuan Zou
Yuanyuan Zou
RLRuoyuan Liao
Ruoyuan Liao
RCRui Cheng
Rui Cheng
HCHuiyee Chung
Huiyee Chung
HZHongqiu Zhu
Hongqiu Zhu
YHYefang Huang
Yefang Huang

14 October 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MLMin Liu
Min Liu
JYJin Yan
Jin Yan
YWYeke Wu
Yeke Wu
HZHongqiu Zhu
Hongqiu Zhu
YHYefang Huang
Yefang Huang
KWKeming Wu
Keming Wu
As an important part of the human intestinal microecology, the intestinal flora is involved in a number of physiological functions of the host. Several studies have shown that imbalance of intestinal flora and its regulation of the intestinal barrier, intestinal immune response, and intestinal flora metabolites (short-chain fatty acids and bile acids) can affect the development and regression of female reproductive disorders. Herbal medicine has unique advantages in the treatment of female reproductive disorders such as polycystic ovary syndrome, endometriosis and premature ovarian insufficiency, although its mechanism of action is still unclear. Therefore, based on the role of intestinal flora in the occurrence and development of female reproduction-related diseases, the progress of research on the diversity, structure and composition of intestinal flora and its metabolites regulated by botanical drugs, Chinese herbal formulas and active ingredients of Chinese herbal medicines is reviewed, with a view to providing reference for the research on the mechanism of action of Chinese herbal medicines in the treatment of female reproductive disorders and further development of new herbal medicines.

4 July 2024 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
LHLiuqing He
Liuqing He
HXHaofei Xu
Haofei Xu
MLMin Liu
Min Liu
YTYing Tan
Ying Tan
SHShiyu Huang
Shiyu Huang
YHYefang Huang
Yefang Huang

1 November 2024 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
XYXiaoxiao Yin
Xiaoxiao Yin
LHLiuqing He
Liuqing He
HXHaofei Xu
Haofei Xu
SLShunping Lou
Shunping Lou
YTYing Tan
Ying Tan
YHYefang Huang
Yefang Huang

1 August 2025 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
JLJunjie Li
Junjie Li
LYLeilei Yang
Leilei Yang
YWYan Wang
Yan Wang
MHMin He
Min He
HZHongqiu Zhu
Hongqiu Zhu
YHYefang Huang
Yefang Huang
Hysteroscopic myomectomy is the first-line treatment for the removal of submucosal myoma in women facing fertility requirements. However, in the face of large diameter type 2 submucosal myoma, patients are at greater risk of complications such as uterine perforation and fluid overload during hysteroscopy. When the diameter of type 2 submucous myoma is greater than 4cm, the three-phase treatment of high intensity focused ultrasound (HIFU), drugs and hysteroscopy is effective and safe. We shared a case of a 30-year-old non-pregnant woman, who had a history of uterine submucous myoma for more than 4 years with symptoms of heavy menstruation, prolonged menstruation and secondary severe anemia. The patient’s initial pelvic magnetic resonance results suggested a type 2 uterine submucous myoma with a diameter of more than 4cm. We first performed HIFU on the patient, followed by the patient’s oral intake of mifepristone tablets for 3 months, and prior to hysteroscopic surgery, the patient’s fibroid type was shifted to type 0, and finally successfully completed hysteroscopic myomectomy (HM). Finally, we conclude that when the diameter of type 2 submucosal myoma exceeds 4 cm, preoperative application of HIFU combined with drug treatment should be considered to maximize the reduction of fibroids, improve symptoms such as anemia and dysmenorrhea, reduce the time required for hysteroscopic surgery, and improve the safety of surgery.